Lanean...
Methods for the Construction of Recombinant Oncolytic Myxoma Viruses
Myxoma virus (MYXV) has proven to be an effective candidate for oncolytic virotherapy in many preclinical cancer models. As a nonhuman pathogen, MYXV does not need to overcome any preexisting antiviral immunity, and its DNA cannot integrate into the host genome, making it an extremely safe vector. M...
Gorde:
| Argitaratua izan da: | Methods Mol Biol |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8082691/ https://ncbi.nlm.nih.gov/pubmed/33108657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/978-1-0716-1012-1_4 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|